Pfizer Inc (PFE) 33.27 $PFE
Better Dividend Stock: Pfizer vs. GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 14, 6:01AM CST
Image source: GlaxoSmithKline. GlaxoSmithKline has an eye-popping dividend yield of 5.75%, but that doesn't necessarily make it the best dividend-paying option available to investors. In fact, with GlaxoSmithKline's product portfolio facing a...
PFE: 33.27 (-0.12), GSK: 39.87 (-0.18)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.27 (-0.12), MRK: 53.03 (unch), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), REGN: 548.90 (-3.63)
Big deal momentum may carry into 2016 for health care
By TOM MURPHY - AP - Fri Nov 13, 1:16PM CST
With $2 trillion in buyouts since January, 2015 has become the year of the megadeal, fueled by free money in a zero-interest rate environment.
CI: 131.57 (+0.18), ANTM: 132.55 (-0.88), PFE: 33.27 (-0.12), ANTX: 44.63 (-0.45), MYL: 48.78 (+5.58)
Allergan Is a Winner -- With or Without Pfizer Deal
at The Street - Fri Nov 13, 7:00AM CST
We'd love to see Pfizer acquire Allergan, but it isn't the only reason we're in the name.
AGN: 299.63 (-0.41), PFE: 33.27 (-0.12), TEVA: 58.01 (-0.32)
5 Things Pfizer Inc. Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 13, 6:39AM CST
Image source: Pfizer. Late last month, pharmaceutical juggernaut Pfizer did what it's done best over the past couple of quarters and handily surpassed Wall Street's third-quarter estimates. Pfizer's headline numbers showed that the...
PFE: 33.27 (-0.12)
3 Top Stocks for Low-Risk Investors
Timothy Green, Matthew DiLallo, and George Budwell, The Motley Fool - Motley Fool - Fri Nov 13, 6:11AM CST
Image source: GotCredit via Flickr. While the riskiest of stocks are often the ones that provide investors with amazing returns, the downside is the very real possibility of a permanent loss of capital. For every high-flying growth stock, there...
AGN: 299.63 (-0.41), PFE: 33.27 (-0.12), XOM: 78.10 (-1.31), VZ: 44.23 (-0.60)
Ask a Fool: What Stocks Are On Your Radar Now?
Matthew Frankel, Selena Maranjian, Jordan Wathen, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Nov 13, 6:00AM CST
Source: Flickr user Rafael Matsunaga . Here at the Fool, we have positive opinions about lots of stocks, but it wouldn't be possible or practical to buy every single stock we like. However, there are some stocks that are especially intriguing...
HAS: 76.01 (-1.84), CFR: 68.03 (-1.18), PFE: 33.27 (-0.12), CLLS: 35.83 (-0.53), ETSY: 8.69 (-0.25)
Watch for Pfizer to Potentially Rebound After Falling 1.04% Yesterday
Comtex SmarTrend(R) - Thu Nov 12, 5:01PM CST
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $33.35 to a high of $33.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $33.39 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 33.27 (-0.12)
SmarTrend Watching for Potential Rebound in Shares of Pfizer After 1.04% Loss
Comtex SmarTrend(R) - Thu Nov 12, 5:00PM CST
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $33.35 to a high of $33.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $33.39 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 33.27 (-0.12)
Pfizer (PFE) Crosses Pivot Point Support at $33.52
Comtex SmarTrend(R) - Thu Nov 12, 11:52AM CST
Shares of Pfizer (NYSE FE) opened today below their pivot of $33.87 and have already reached the first level of support at $33.52. Should the shares continue to fall, the support pivots of $33.31 and $32.75 will be of interest.
PFE: 33.27 (-0.12)
Viamet Appoints Dr. Volker Herrmann as Chief Commercial Officer
Business Wire - Thu Nov 12, 9:30AM CST
Viamet Pharmaceuticals, Inc. today announced the appointment of Volker Herrmann, M.D., M.B.A., as Chief Commercial Officer. Dr. Hermann is an accomplished pharmaceutical executive with extensive experience in sales, marketing, commercial strategy and market access. Prior to joining Viamet, Dr. Herrmann served as Head of Global Strategy, Commercial Development & Global Marketing for the Vaccines Business Unit of Pfizer Inc. At Pfizer, he contributed to the successful performance of several of the most significant brands in the pharmaceutical marketplace.
PFE: 33.27 (-0.12)
Boston Scientific Slides On Proposed Device Coverage
at Investor's Business Daily - Wed Nov 11, 4:25PM CST
Medical-device giant Boston Scientific (BSX) fell 4.2% Wednesday after the U.S. government proposed limiting coverage of its new heart implant. Late Tuesday, the Centers for Medicare and Medicaid Services (CMS) issued the proposed guidelines covering...
BSX: 17.51 (-0.23), JNJ: 99.88 (-0.39), PFE: 33.27 (-0.12)
Asian stocks mixed as attention turns to China data
By YURI KAGEYAMA - AP - Tue Nov 10, 10:02PM CST
TOKYO (AP) — Asian shares were mixed Wednesday as attention focused on key economic indicators from China that will set the tone for regional growth prospects.
PFE: 33.27 (-0.12), UNH: 111.41 (-1.41), AAPL: 112.34 (-3.38)
Global Market Study on Osteoporosis Drugs 2015-2022 - Market is Expected to Grow from an Estimated US$5,482.6 Mn in 2015 to Us$7,342.2 Mn by 2022
M2 - Tue Nov 10, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/97pwpv/global_market) has announced the addition of the "Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022" report to their offering. The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn in 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period. The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market. However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits growth of the market. North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the fastest growing type of osteoporosis drugs. Bisphosphonates are the most commonly prescribed medication for treatment and prevention of osteoporosis. The global bisphosphonates drugs market is expected to grow from an estimated US$5,482.6 Mn in 2015 to US$7,342.2 Mn by 2022 at a CAGR of 4.3% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Drug Type Chapter 7 Market Size and Forecast by Geography Chapter 8 Competitive Scenario Chapter 9 Company Profiles - Actavis plc - Amgen, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd - GlaxoSmithKline plc - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Pfizer, Inc - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/97...bal_market
NVO: 52.93 (-0.57), PFE: 33.27 (-0.12), MRK: 53.03 (unch), AMGN: 151.55 (+0.57), TEVA: 58.01 (-0.32), LLY: 79.55 (-0.31), GSK: 39.87 (-0.18), NVS: 86.28 (-0.58)
United States Bacterial Conjunctivitis Drugs Market Study 2015 - Fluoroquinolones to be the Largest Segment by 2024
M2 - Tue Nov 10, 8:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/nhdchq/the_u_s_market) has announced the addition of the "The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024" report to their offering. The cost of treating bacterial conjunctivitis ranges from USD 377 million to USD 857 million annually in the U.S It also quoted that majority of conjunctivitis patients are originally treated by primary care physicians rather than eye care professionals. Around 1% of all primary care office visits in the U.S. are related to conjunctivitis. Bacterial infestation is the second most common cause of infectious conjunctivitis and accounts for 50% to 75% cases among children. This pattern was observed more frequently from December 2012 to April 2013.Thus, potential incidence of bacterial conjunctivitis is one of the major drivers of the bacterial conjunctivitis drugs market in the U.S. However, increasing genericization of antibacterial drugs coupled with upcoming patent expirations,and such few prominent factors are weakening the growth of the market in the near future. Currently, the market is highly fragmented and competitive due to the involvement of both large and small pharmaceutical companies. Actavis plc (now Allergan plc), Akorn, Inc.,Bayer AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc.are the major players operating in the bacterial conjunctivitis drugs market in the U.S. During the course of this study it has been observed that majority of the players are focusing on expanding their geographical reach and distribution network through mergers and acquisitions as well as through collaborations with other potential organizations operating in this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment Chapter 6 Recommendations Chapter 7 Company Profiles - Actavis plc (now Allergan plc) - Akorn, Inc. - Bayer AG - F. Hoffmann-La Roche Ltd. - Merck & Co., Inc. - Novartis AG - Perrigo Company plc - Pfizer, Inc. - Santen Pharmaceutical Co., Ltd. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/nh...u_s_market
PRGO: 146.90 (-9.65), AKRX: 28.57 (+1.24), PFE: 33.27 (-0.12), MRK: 53.03 (unch), VRX.TO: 100.53 (+2.39), NVS: 86.28 (-0.58)
3 Biotech Stocks That Are Rocketing Higher
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 09, 2:41PM CST
Source: Flickr user Steve Jurvetson The biotech industry may have lost a bit of its luster with investors lately, but some biotech stocks are still generating eye-popping returns that suggest people remain willing to bet on game-changing medicine....
PFE: 33.27 (-0.12), CLLS: 35.83 (-0.53), FOLD: 10.48 (+0.49), CELG: 107.49 (-1.53), XLRN: 35.47 (-0.09)
Global Oligodendroglioma Pipeline Review, H2 2015 Edition
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/n9ncqk/oligodendroglioma) has announced the addition of the "Oligodendroglioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Axelar AB - Boehringer Ingelheim GmbH - Cavion LLC - Celgene Corporation - Celldex Therapeutics, Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncolytics Biotech Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. For more information visit http://www.researchandmarkets.com/research/n9...ndroglioma
ONCY: 0.33 (-0.02), PFE: 33.27 (-0.12), CLDX: 14.23 (+0.22), LLY: 79.55 (-0.31), NVS: 86.28 (-0.58), CELGZ: 1.17 (-0.03)
Hyperlipidemia - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rs6k8/hyperlipidemia) has announced the addition of the "Hyperlipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - BCWorld Pharm Co. Ltd. - Catabasis Pharmaceuticals, Inc. - CJ CheilJedang Corp. - Daewoong Pharmaceutical Co., Ltd. - HanAll Biopharma Co., Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Pfizer Inc. - Pharmena SA - Prometheon Pharma, LLC - Protalix BioTherapeutics, Inc. - TSH Biopharm Corporation Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/3r...rlipidemia
ISIS: 62.65 (+0.61), PFE: 33.27 (-0.12), AMGN: 151.55 (+0.57)
Better Dividend Stock: Pfizer vs. GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 14, 6:01AM CST
Image source: GlaxoSmithKline. GlaxoSmithKline has an eye-popping dividend yield of 5.75%, but that doesn't necessarily make it the best dividend-paying option available to investors. In fact, with GlaxoSmithKline's product portfolio facing a...
PFE: 33.27 (-0.12), GSK: 39.87 (-0.18)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.27 (-0.12), MRK: 53.03 (unch), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), REGN: 548.90 (-3.63)
Big deal momentum may carry into 2016 for health care
By TOM MURPHY - AP - Fri Nov 13, 1:16PM CST
With $2 trillion in buyouts since January, 2015 has become the year of the megadeal, fueled by free money in a zero-interest rate environment.
CI: 131.57 (+0.18), ANTM: 132.55 (-0.88), PFE: 33.27 (-0.12), ANTX: 44.63 (-0.45), MYL: 48.78 (+5.58)
Allergan Is a Winner -- With or Without Pfizer Deal
at The Street - Fri Nov 13, 7:00AM CST
We'd love to see Pfizer acquire Allergan, but it isn't the only reason we're in the name.
AGN: 299.63 (-0.41), PFE: 33.27 (-0.12), TEVA: 58.01 (-0.32)
5 Things Pfizer Inc. Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 13, 6:39AM CST
Image source: Pfizer. Late last month, pharmaceutical juggernaut Pfizer did what it's done best over the past couple of quarters and handily surpassed Wall Street's third-quarter estimates. Pfizer's headline numbers showed that the...
PFE: 33.27 (-0.12)
3 Top Stocks for Low-Risk Investors
Timothy Green, Matthew DiLallo, and George Budwell, The Motley Fool - Motley Fool - Fri Nov 13, 6:11AM CST
Image source: GotCredit via Flickr. While the riskiest of stocks are often the ones that provide investors with amazing returns, the downside is the very real possibility of a permanent loss of capital. For every high-flying growth stock, there...
AGN: 299.63 (-0.41), PFE: 33.27 (-0.12), XOM: 78.10 (-1.31), VZ: 44.23 (-0.60)
Ask a Fool: What Stocks Are On Your Radar Now?
Matthew Frankel, Selena Maranjian, Jordan Wathen, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Nov 13, 6:00AM CST
Source: Flickr user Rafael Matsunaga . Here at the Fool, we have positive opinions about lots of stocks, but it wouldn't be possible or practical to buy every single stock we like. However, there are some stocks that are especially intriguing...
HAS: 76.01 (-1.84), CFR: 68.03 (-1.18), PFE: 33.27 (-0.12), CLLS: 35.83 (-0.53), ETSY: 8.69 (-0.25)
Watch for Pfizer to Potentially Rebound After Falling 1.04% Yesterday
Comtex SmarTrend(R) - Thu Nov 12, 5:01PM CST
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $33.35 to a high of $33.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $33.39 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 33.27 (-0.12)
SmarTrend Watching for Potential Rebound in Shares of Pfizer After 1.04% Loss
Comtex SmarTrend(R) - Thu Nov 12, 5:00PM CST
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $33.35 to a high of $33.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $33.39 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 33.27 (-0.12)
Pfizer (PFE) Crosses Pivot Point Support at $33.52
Comtex SmarTrend(R) - Thu Nov 12, 11:52AM CST
Shares of Pfizer (NYSE
FE) opened today below their pivot of $33.87 and have already reached the first level of support at $33.52. Should the shares continue to fall, the support pivots of $33.31 and $32.75 will be of interest. PFE: 33.27 (-0.12)
Viamet Appoints Dr. Volker Herrmann as Chief Commercial Officer
Business Wire - Thu Nov 12, 9:30AM CST
Viamet Pharmaceuticals, Inc. today announced the appointment of Volker Herrmann, M.D., M.B.A., as Chief Commercial Officer. Dr. Hermann is an accomplished pharmaceutical executive with extensive experience in sales, marketing, commercial strategy and market access. Prior to joining Viamet, Dr. Herrmann served as Head of Global Strategy, Commercial Development & Global Marketing for the Vaccines Business Unit of Pfizer Inc. At Pfizer, he contributed to the successful performance of several of the most significant brands in the pharmaceutical marketplace.
PFE: 33.27 (-0.12)
Boston Scientific Slides On Proposed Device Coverage
at Investor's Business Daily - Wed Nov 11, 4:25PM CST
Medical-device giant Boston Scientific (BSX) fell 4.2% Wednesday after the U.S. government proposed limiting coverage of its new heart implant. Late Tuesday, the Centers for Medicare and Medicaid Services (CMS) issued the proposed guidelines covering...
BSX: 17.51 (-0.23), JNJ: 99.88 (-0.39), PFE: 33.27 (-0.12)
Asian stocks mixed as attention turns to China data
By YURI KAGEYAMA - AP - Tue Nov 10, 10:02PM CST
TOKYO (AP) — Asian shares were mixed Wednesday as attention focused on key economic indicators from China that will set the tone for regional growth prospects.
PFE: 33.27 (-0.12), UNH: 111.41 (-1.41), AAPL: 112.34 (-3.38)
Global Market Study on Osteoporosis Drugs 2015-2022 - Market is Expected to Grow from an Estimated US$5,482.6 Mn in 2015 to Us$7,342.2 Mn by 2022
M2 - Tue Nov 10, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/97pwpv/global_market) has announced the addition of the "Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022" report to their offering. The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn in 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period. The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market. However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits growth of the market. North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the fastest growing type of osteoporosis drugs. Bisphosphonates are the most commonly prescribed medication for treatment and prevention of osteoporosis. The global bisphosphonates drugs market is expected to grow from an estimated US$5,482.6 Mn in 2015 to US$7,342.2 Mn by 2022 at a CAGR of 4.3% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Drug Type Chapter 7 Market Size and Forecast by Geography Chapter 8 Competitive Scenario Chapter 9 Company Profiles - Actavis plc - Amgen, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd - GlaxoSmithKline plc - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Pfizer, Inc - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/97...bal_market
NVO: 52.93 (-0.57), PFE: 33.27 (-0.12), MRK: 53.03 (unch), AMGN: 151.55 (+0.57), TEVA: 58.01 (-0.32), LLY: 79.55 (-0.31), GSK: 39.87 (-0.18), NVS: 86.28 (-0.58)
United States Bacterial Conjunctivitis Drugs Market Study 2015 - Fluoroquinolones to be the Largest Segment by 2024
M2 - Tue Nov 10, 8:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/nhdchq/the_u_s_market) has announced the addition of the "The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024" report to their offering. The cost of treating bacterial conjunctivitis ranges from USD 377 million to USD 857 million annually in the U.S It also quoted that majority of conjunctivitis patients are originally treated by primary care physicians rather than eye care professionals. Around 1% of all primary care office visits in the U.S. are related to conjunctivitis. Bacterial infestation is the second most common cause of infectious conjunctivitis and accounts for 50% to 75% cases among children. This pattern was observed more frequently from December 2012 to April 2013.Thus, potential incidence of bacterial conjunctivitis is one of the major drivers of the bacterial conjunctivitis drugs market in the U.S. However, increasing genericization of antibacterial drugs coupled with upcoming patent expirations,and such few prominent factors are weakening the growth of the market in the near future. Currently, the market is highly fragmented and competitive due to the involvement of both large and small pharmaceutical companies. Actavis plc (now Allergan plc), Akorn, Inc.,Bayer AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc.are the major players operating in the bacterial conjunctivitis drugs market in the U.S. During the course of this study it has been observed that majority of the players are focusing on expanding their geographical reach and distribution network through mergers and acquisitions as well as through collaborations with other potential organizations operating in this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment Chapter 6 Recommendations Chapter 7 Company Profiles - Actavis plc (now Allergan plc) - Akorn, Inc. - Bayer AG - F. Hoffmann-La Roche Ltd. - Merck & Co., Inc. - Novartis AG - Perrigo Company plc - Pfizer, Inc. - Santen Pharmaceutical Co., Ltd. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/nh...u_s_market
PRGO: 146.90 (-9.65), AKRX: 28.57 (+1.24), PFE: 33.27 (-0.12), MRK: 53.03 (unch), VRX.TO: 100.53 (+2.39), NVS: 86.28 (-0.58)
3 Biotech Stocks That Are Rocketing Higher
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 09, 2:41PM CST
Source: Flickr user Steve Jurvetson The biotech industry may have lost a bit of its luster with investors lately, but some biotech stocks are still generating eye-popping returns that suggest people remain willing to bet on game-changing medicine....
PFE: 33.27 (-0.12), CLLS: 35.83 (-0.53), FOLD: 10.48 (+0.49), CELG: 107.49 (-1.53), XLRN: 35.47 (-0.09)
Global Oligodendroglioma Pipeline Review, H2 2015 Edition
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/n9ncqk/oligodendroglioma) has announced the addition of the "Oligodendroglioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Axelar AB - Boehringer Ingelheim GmbH - Cavion LLC - Celgene Corporation - Celldex Therapeutics, Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncolytics Biotech Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. For more information visit http://www.researchandmarkets.com/research/n9...ndroglioma
ONCY: 0.33 (-0.02), PFE: 33.27 (-0.12), CLDX: 14.23 (+0.22), LLY: 79.55 (-0.31), NVS: 86.28 (-0.58), CELGZ: 1.17 (-0.03)
Hyperlipidemia - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rs6k8/hyperlipidemia) has announced the addition of the "Hyperlipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - BCWorld Pharm Co. Ltd. - Catabasis Pharmaceuticals, Inc. - CJ CheilJedang Corp. - Daewoong Pharmaceutical Co., Ltd. - HanAll Biopharma Co., Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Pfizer Inc. - Pharmena SA - Prometheon Pharma, LLC - Protalix BioTherapeutics, Inc. - TSH Biopharm Corporation Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/3r...rlipidemia
ISIS: 62.65 (+0.61), PFE: 33.27 (-0.12), AMGN: 151.55 (+0.57)
